Physician profile
Shaun Cooper
NPI 1023675352
$6,174.02
in general payments reported to CMS, 2019-2025
27 companies · $1,939 in 2025
The $1,939 reported for 2025 was more than what 75% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $519 · 2021: $397 · 2022: $13.25 · 2023: $1,319 · 2024: $1,986 · 2025: $1,939.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,862 · Travel and Lodging: $284 · Education: $98.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,862.12 |
| Travel and Lodging | $283.96 |
| Education | $98.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,643.42 | 2020-2025 | Natrelle Saline-Filled Breast Implants, Revolve, Skyrizi |
| Amgen INC. | $733.77 | 2020-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $560.12 | 2023-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $449.81 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $381.16 | 2020-2025 | |
| Genzyme Corporation | $376.52 | 2023-2025 | |
| Lilly USA, LLC | $299.69 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Sun Pharmaceutical Industries INC. | $283.75 | 2020-2025 | Absorica Ld, Winlevi |
| Janssen Biotech, INC. | $265.03 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Incyte Corporation | $237.83 | 2023-2025 | Opzelura |
| Pfizer INC. | $237.78 | 2023-2025 | |
| Galderma Laboratories, L.P. | $111.51 | 2024-2025 | Nemluvio |
| Leo Pharma INC. | $105.28 | 2024-2025 | Adbry, Anzupgo |
| Ucb, INC. | $88.70 | 2025 | Bimzelx |
| Mayne Pharma Commercial LLC | $82.70 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $47.26 | 2023-2024 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $41.78 | 2020-2021 | |
| Cipher Pharmaceuticals US LLC | $31.09 | 2025 | Natroba, Spinosad |
| Dermavant Sciences, INC. | $31.03 | 2024 | Vtama |
| Botanix Sb INC | $24.73 | 2025 | Sofdra |
| Journey Medical Corporation | $23.51 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.06 | 2023 | Spevigo |
| Verrica Pharmaceuticals INC. | $21.41 | 2025 | Ycanth |
| Genentech USA, INC. | $20.80 | 2024 | Xolair |
| Fidia Pharma USA INC. | $20.40 | 2025 | |
| Tempus Ai, INC | $18.12 | 2024 | Merlin Test |
| Biofrontera INC. | $13.76 | 2024 | Ameluz, Xepi, Bf-Rhodoled |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.